FOLH1 and prostate carcinoma: In terms of kinetic metrics, the K3 value effectively distinguished between abnormal lesions and healthy organs with increased absorption of 68Ga-PSMA-11, and is expected to gain broader clinical application as an imaging biomarker for differentiating pathological and non-specific 68Ga-PSMA-11 uptake in prostate cancer patients (79).